Long-term outcomes of unilateral iliac stenting and femorofemoral crossover bypass for bilateral extensive iliac disease

Zia Ur Rehman 💿

The Aga Khan University, Department of Surgery, Karachi, Pakistan

ABSTRACT

In recent years, hybrid procedures are routinely used in high-risk patients with severe aortoiliac occlusive disease. However, little is known regarding their long-term results, particularly in developing countries. Herein, we report three cases of bilateral severe iliac artery stenoiss presenting with critical limb ischemia. All these patients underwent unilateral iliac artery stenting with femorofemoral crossover grafting. All patients had smooth recovery and demonstrated complete resolution of symptoms. The patients were symptom-free with patent grafts during a mean follow-up of four years.

Keywords: Femorofemoral bypass grafting; graft patency; iliac stenosis.

For severe aortoiliac occlusive disease, conventional approach is aortobifemoral bypass (ABF) grafting in low-risk patients.^[1] The early patency of ABF for critical limb ischemia is up to 100% and decreases to 87% at five years.^[1] It is associated with major perioperative morbidity and mortality.^[1] Extraanatomical bypasses are performed for high-risk patients who are in danger of limb loss. However, they are associated with limited patency. In patients with complete occlusion of the ipsilateral common and external iliac arteries and with contralateral iliac disease, stenting of the contralateral iliac artery with a crossover femoral-to-femoral artery bypass is an alternative to surgical ABF.^[2] These hybrid procedures have been increasingly performed with good results.^[2] They are also effective, as they need minimal surgical dissection and exposure and with less physiological disturbance, although their durability is still under observation. There are scanty data regarding the long-term patency of these procedures, particularly in developing countries. Herein, we present three cases of ipsilateral iliac stenting and femorofemoral

crossover bypass (FFB) for critical limb ischemia with their long-term follow-up results.

CASE REPORT

All patients presented with critical limb ischemia. The details of patients are given in Table 1. All patients underwent unilateral iliac stenting in radiology suite followed by FFB in the operation theater. The latter was performed under general anesthesia. Standard groin dissection was done to expose the femoral arteries. An externally supported polytetrafluoroethylene (PTFE) graft (6 or 8 mm in size) was used as the conduit. The graft was placed into the suprapubic subcutaneous space. In all patients, FFB was performed immediate after stenting on the same day. Restoration of the circulation was confirmed with palpable distal pulses at the end of the procedure. Postoperatively, all patients had smooth recovery. During a mean followup of four years, all patients had patent grafts with asymptomatic limbs. At discharge, at six months, and

Correspondence: Zia Ur Rehman, MD. The Aga Khan University, Department of Surgery, Stadium Road, P.O. Box 3500, 74800 Karachi, Pakistan. e-mail: ziaur.rehman@aku.edu

Citation:

Rehman ZU. Long-term outcomes of unilateral iliac stenting and femorofemoral crossover bypass for bilateral extensive iliac disease. Turk J Vasc Surg 2019;28(3):191-193.

Received: September 03, 2018 Accepted: September 24, 2018 Published online: October 22, 2018

| Details of patients t Age (years)/Gender 83/Female 60/Male 63/Male | ceated with unilateral Co-morbidities Hypertension DM DM Ex-smoker Hypertension DM Congenital solitary Kidney Smoker Hypertension DM | Iliac stenting and Presentation Tissue loss Rest pain Rest pain | femorofemoral c Pre-operative investigation CTA CTA CTA CTA | rossover bypass gra Size of iliac stent Self expanding 10×94 mm nitinol Self expanding 8×120 mm Self expanding | fting Graft material 8 mm PTFE 6 mm PTFE 8 mm PTFE | Primary patency (months) 48 56 46 | Secondary intertervention No No | Limb salvage Yes Yes | Outcome Alive and well, graft patent Alive and well Died (MI), graft patent |
|--|--|---|---|--|--|--|---|--|--|
| s mellitus; CKD: Chronic ki | Smoker Iney disease; CTA: Computed to | mography angiography; P' | TFE: Polytetrafluoroethy | rlene; IHD: Ischemic heart di | isease; MI: Myocardial ini | farction. | | | - |
| | Details of patients ti Age (years)/Gender 83/Female 60/Male 63/Male 63/Male | Details of patients treated with unilateral Age (years)/Gender Co-morbidities 83/Female Hypertension 83/Female Hypertension S3/Female Hypertension BA DM CMD Ex-smoker 60/Male Hypertension DM DM BA DM BA DM BA DM BA BA BA DM BA BA BA DM BA BA BA | Details of patients treated with unilateral iliac stenting and Age (years)/Gender Co-morbidities Presentation 83/Female Hypertension Tissue loss DM Tissue loss CKD Ex-smoker 60/Male Hypertension Rest pain DM Hypertension Rest pain DM Smoker 63/Male Hypertension Rest pain Smoker Smo | Details of patients treated with unilateral iliac stenting and femorofemoral c Age (years)/Gender Co-morbidities Presentation Pre-operative investigation 83/Female Hypertension Tissue loss CTA 83/Female Hypertension Tissue loss CTA 83/Female Hypertension Rest pain CTA 60/Male Hypertension Rest pain CTA 60/Male Hypertension Rest pain CTA 63/Male Hypertension Rest pain CTA 63/Male Hypertension Rest pain CTA 0 DM Smoker CTA 63/Male Hypertension Rest pain CTA 83/Male Hypertension Rest pain CTA 0 DM Smoker Smoker 0 DM Smoker Smoker | Details of patients treated with unilateral liliac stenting and femorofemoral crossover bypass gra Age (years)/Gender Co-morbidities Presentation Pre-operative Size of iliac stent Age (years)/Gender Co-morbidities Presentation Pre-operative Size of iliac stent AsyFemale Hypertension Tissue loss CTA Self expanding B3/Female Hypertension Tissue loss CTA Self expanding B3/Female Hypertension Rest pain CTA Self expanding DM DM Ex-smoker Nah Self expanding B3/Female Hypertension Rest pain CTA Self expanding DM DM Congenital solitary Self expanding Self expanding Sidney Hypertension Rest pain CTA Self expanding B3/Male < | Details of patients treated with unilateral liliac stenting and femorofemoral crossover bypass grafting Age (years)/Gender Co-morbidities Presentation Pre-operative Size of lilac stent Graft material Age (years)/Gender Co-morbidities Presentation Pre-operative Size of lilac stent Graft material B3/Female Hypertension Tissue loss CTA Self expanding 8 mm B3/Female Hypertension Rest pain CTA Self expanding 6 mm B3/Female Hypertension Rest pain CTA Self expanding 6 mm B60/Male Hypertension Rest pain CTA Self expanding 6 mm B0/M DM DM Self expanding 6 mm B0/M Hypertension Rest pain CTA Self expanding 6 mm B3/Male Hypertension Rest pain CTA Self expanding 6 mm B3/Male Hypertension Rest pain CTA Self expanding 8 mm B3/Male Hypertension Rest pain CTA Self expanding 8 mm B3/Male | Details of patients treated with unilateral lilac stenting and femorofemoral crossover bypass grafting Age (years)/Gender Co-morbidities Presentation Pre-operative Size of lilac stent Amaterial Primary patency (months) Age (years)/Gender Co-morbidities Tissue loss CTA Self expanding Rom 48 S3/Female Hypertension Tissue loss CTA Self expanding Rom 48 0/Male Hypertension Rest pain CTA Self expanding Rom 48 0/Male Hypertension Rest pain CTA Self expanding Rom 56 0/Male Hypertension Rest pain CTA Self expanding Rom 56 0/Male Hypertension Rest pain CTA Self expanding Rom 56 0/Male Hypertension Rest pain CTA Self expanding Rom 56 0/Male Hypertension Rest pain CTA Self expanding Rom 56 0/Male Hypertension Rest pain CTA Self expanding Rom 60 | Details of patients treated with unilateral lilac stenting and femorofemoral crossover bypass grafting Age (veras)(Gender Co-morbidities Presentation Pre-operative Size of lilac stent Frimary patency Secondary Age (veras)(Gender Co-morbidities Presentation Pre-operative Size of lilac stent Graft material Primary patency Secondary S3/Female Hypertension Tssue loss CTA Self expanding 8 mm 48 No S3/Female Hypertension Rest pain CTA Self expanding 6 mm 48 No MID DM No No Self expanding 6 mm 76 No S3/Female Hypertension Rest pain CTA Self expanding 6 mm 46 No MiD DM No Self expanding 6 mm 76 No No S3/Male Hypertension Rest pain CTA Self expanding 8 mm 46 No SaMale Hypertension Rest pain CTA Self expanding 8 mm 76 No SaMer | Details of patients treated with unilateral litac stenting and femorofemoral crossover bypass grafting Age (vars)/Cender Co-unrbidities Presentation Pre-operative Size of litac stent Carf material Primary patency Secondary Limary patency S |

annually thereafter, all patients had ankle-brachial

DISCUSSION

index measurements.

The ABF grafting has remained the mainstay of treatment for symptomatic aortoiliac occlusive disease, being both durable and effective.^[3] The patency rate of ABF is about 85 to 90% at five years.^[4] However, it is an extensive surgical procedure with a high rate of associated complications (4 to 20%) and a mortality rate of 3 to 5%.^[3] Hybrid procedures have emerged as a method of revascularization in patients with critical lower extremity ischemia having multilevel arterial occlusive disease.

In the literature, for unilateral iliac disease, FFB has both good short and long results;^[5] however, in practice, iliac disease is usually more extensive rather than focal, involving both the iliac orifices in most of cases. It may compromises the patency of FFB. Earlier reports showed significant donor iliac stenosis as a risk for subsequent FFB failure.^[6] The advent of endovascular techniques for the treatment of arterial occlusive disease has expanded the anatomical profile of patients deemed suitable to undergo FFB. Patients with donor inflow disease are anatomically eligible for a concomitant endovascular intervention at the time of surgery. Despite this evolution in practice, the reports of outcomes of FFB with an ipsilateral intervention remain somewhat limited. Previous reports have shown mixed results using donor iliac intervention in conjunction with FFB for patients with bilateral aortoiliac occlusive disease. Lopez-Galarza et al.^[7] documented the associated five-year primary patency as 51% in a review of 18 patients who underwent FFB grafting with adjunctive iliac stenting in the setting of stenosis shorter than 3 cm.^[7] Aburahma et al.^[6] reported a series of 41 patients who underwent FFB, in whom 92% underwent iliac stenting in the setting of iliac lesions >5 cm in length, compared to with 14% who underwent associated stenting in the setting of a lesion <5 cm in length. For the durability of crossover grafting, it is important to handle contralateral iliac disease. There are series showing that selected iliac artery stenting has also improved the outcome of crossover bypass in patients with a suboptimal donor iliac artery.^[8] Similar results were duplicated in our case patients.

Furthermore, conduit for FFB is always a concern in terms of its long-term results. We used the PTFE as conduit in all patients. We believe using native venous grafts may add more operative time and can be at the cost of associated wound morbidity.

In conclusion, early and long-term results are encouraging with donor iliac stenting with FFB bypass in patients with symptomatic severe bilateral iliac disease.

Declaration of conflicting interests

The author declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding

The author received no financial support for the research and/or authorship of this article.

REFERENCES

- de Vries SO, Hunink MG. Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis. J Vasc Surg 1997;26:558-69.
- 2. Aho PS, Venermo M. Hybrid procedures as a novel technique in the treatment of critical limb ischemia.

Scand J Surg 2012;101:107-13.

- Sachwani GR, Hans SS, Khoury MD, King TF, Mitsuya M, Rizk YS, et al. Results of iliac stenting and aortofemoral grafting for iliac artery occlusions. J Vasc Surg 2013;57:1030-7.
- Chiu KW, Davies RS, Nightingale PG, Bradbury AW, Adam DJ. Review of direct anatomical open surgical management of atherosclerotic aorto-iliac occlusive disease. Eur J Vasc Endovasc Surg 2010;39:460-71.
- Park KM, Park YJ, Kim YW, Hyun D, Park KB, Do YS, et al. Long Term Outcomes of Femorofemoral Crossover Bypass Grafts. Vasc Specialist Int 2017;33:55-8.
- Aburahma AF, Robinson PA, Cook CC, Hopkins ES. Selecting patients for combined femorofemoral bypass grafting and iliac balloon angioplasty and stenting for bilateral iliac disease. J Vasc Surg 2001;33:93-9.
- Lopez-Galarza LA, Ray LI, Rodriguez-Lopez J, Diethrich EB. Combined percutaneous transluminal angioplasty, iliac stent deployment, and femorofemoral bypass for bilateral aortoiliac occlusive disease. J Am Coll Surg 1997;184:249-58.
- Criado E, Burnham SJ, Tinsley EA Jr, Johnson G Jr, Keagy BA. Femorofemoral bypass graft: analysis of patency and factors influencing long-term outcome. J Vasc Surg 1993;18:495-504.